Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation

Digestive and Liver Disease

Volumn 44, Issue 5, 2012, Pages 432-437

  Weinmann, Arndt ^a   Niederle, Ina Maria ^a   Koch, Sandra ^a   Hoppe Lotichius, Maria ^a   Heise, Michael ^a   Düber, Christoph ^a   Schuchmann, Marcus ^a   Otto, Gerd ^a   Galle, Peter Robert ^a   Wörns, Marcus Alexander ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Advanced disease; Liver cancer; Posttransplant recurrence; Targeted therapy

Indexed keywords

DOXORUBICIN; GEMCITABINE; LOPERAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALIPLATIN; RAPAMYCIN; SORAFENIB; TACROLIMUS; UREA;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; TIME; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS;

EID: 84859211982     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.12.009     Document Type: Article

References (48)

1. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
4. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
5. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
6. Roayaie S., Schwartz J.D., Sung M.W., et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004, 10:534-540.
7. Schwartz M., Roayaie S., Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. J Hepatol 2005, 43:584-589.
8. Davis E., Wiesner R., Valdecasas J., et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2011, 17:162-166.
9. Worns M.A., Weinmann A., Schuchmann M., et al. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009, 27:175-188.
10. Lee J.O., Kim D.Y., Lim J.H., et al. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 2009, 24:800-805.
11. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
12. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
13. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
14. Yoon D.H., Ryoo B.Y., Ryu M.H., et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010, 40:768-773.
15. Kim R., El-Gazzaz G., Tan A., et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010, 79:62-66.
16. Tan W.F., Qiu Z.Q., Yu Y., et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin 2010, 31:1643-1648.
17. Valdivieso A., Bustamante J., Gastaca M., et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010, 42:660-662.
18. Yeganeh M., Finn R.S., Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009, 9:2851-2854.
19. Wang Y., Speeg K.V., Washburn W.K., et al. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World J Gastroenterol 2010, 16:5518-5522.
20. Bhoori S., Toffanin S., Sposito C., et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010, 52:771-775.
21. Waidmann O., Hofmann W.P., Zeuzem S., et al. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. J Hepatol 2011, 54:396-398.
22. Feun L., Levi D., Moon J., et al. Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation. J Clin Oncol 2009, 27(suppl; abstr e15579).
23. Herden U., Fischer L., Schafer H., et al. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. Transplantation 2010, 90:98-99.
24. Takahara T., Nitta H., Hasegawa Y., et al. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor: two case reports. Transplant Proc 2011, 43:2800-2805.
25. Gomez-Martin C., Bustamante J., Castroagudin J.F., et al. Efficacy and safety of sorafenib in combination with mTOR inhibitors in recurrent hepatocarcinoma after liver transplant. Liver Transpl 2011, September 19 (epub ahead of print).
26. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300.
27. Yokoyama I., Carr B., Saitsu H., et al. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991, 68:2095-2100.
28. Vivarelli M., Cucchetti A., Piscaglia F., et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005, 11:497-503.
29. Majno P., Giostra E., Mentha G. Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma?. J Hepatol 2005, 43:577-584.
30. Worns M.A., Weinmann A., Pfingst K., et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009, 43:489-495.
31. Pinter M., Sieghart W., Graziadei I., et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009, 14:70-76.
32. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
33. Villanueva A., Chiang D.Y., Newell P., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135:1972-1983. 83 e1-11.
34. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
35. Zimmerman M.A., Trotter J.F., Wachs M., et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008, 14:633-638.
36. Toso C., Merani S., Bigam D.L., et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010, 51:1237-1243.
37. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
38. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
39. Worns M.A., Schuchmann M., Duber C., et al. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 2010, 79:85-92.
40. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
41. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.
42. Otto G., Herber S., Heise M., et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006, 12:1260-1267.
43. Piguet A.C., Semela D., Keogh A., et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008, 49:78-87.
44. Huynh H., Chow K.H., Soo K.C., et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2009, 13:1371-1380.
45. Wang Z., Zhou J., Fan J., et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008, 14:5124-5130.
46. Huynh H., Ngo V.C., Koong H.N., et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009, 13:2673-2683.
47. Newell P., Toffanin S., Villanueva A., et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009, 51:725-733.
48. Finn R.S., Poon R.T.P., Yau T., et al. Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011, 29(suppl; abstr 4074).